5-Amino-1MQ dosage protocols center on this selective, cell-permeable NNMT (Nicotinamide N-methyltransferase) inhibitor studied for its potential to support fat metabolism, preserve lean muscle mass, and elevate intracellular NAD+ levels. By blocking NNMT, 5-Amino-1MQ may help restore cellular energy balance and activate SIRT1 pathways associated with metabolic efficiency.
Goal: Support metabolic efficiency through NNMT inhibition, potentially enhancing fat oxidation and NAD+ levels.
Schedule: Daily subcutaneous injections; each 50 mg vial provides 10 to 20 days of research material.
Dose Range: 2.5 to 5 mg once or twice daily.
Reconstitution: 4.0 mL per 50 mg vial (12.5 mg/mL).
Storage: Lyophilized frozen at -20 °C; reconstituted refrigerated at 2 to 8 °C.
Goal: Support tissue-healing and recovery processes based on preclinical evidence.
Schedule: Daily subcutaneous injections for 8 to 12 weeks (extend to 16 weeks if desired).
Dose: Range200 to 600 mcg daily with gradual titration.
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL).
Storage: Lyophilized frozen; reconstituted refrigerated; avoid freeze-thaw.
Once-daily subcutaneous educational protocol for skin rejuvenation, collagen synthesis, wound healing, and tissue repair. GHK-Cu dosage protocols utilize this naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) to support skin rejuvenation, wound healing, and tissue repair. GHK-Cu stimulates collagen and elastin production, promotes angiogenesis, and delivers powerful antioxidant and anti-inflammatory benefits.
Goal: Support skin rejuvenation, collagen synthesis, wound healing, and anti-aging tissue repair.
Schedule: Daily subcutaneous injections, 5 days on / 2 days off, for 8 to 12 weeks.
Dose Range: 1 to 2 mg daily with gradual titration.
Reconstitution: 3.0 mL per 100 mg vial (~33.3 mg/mL) for accurate unit measurements.
Storage: Lyophilized frozen at -20 °C; reconstituted refrigerated; use within 30 days.
Support comprehensive tissue healing through synergistic peptide mechanisms:
mg) vial) Once-daily subcutaneous protocol for combined regenerative peptide research. The GLOW blend combines GHK-Cu (collagen synthesis, antioxidant, anti-inflammatory), BPC-157 (tissue repair, microcirculation, anti-inflammatory), and TB-500 (cell migration, angiogenesis, scar reduction) for synergistic regenerative research.
Goal: Support comprehensive tissue healing through synergistic peptide mechanisms: collagen synthesis (GHK-Cu), cell migration and angiogenesis (TB-500), and localized repair with anti-inflammatory effects (BPC-157).
Schedule: Daily subcutaneous injections for 4 weeks, followed by a 2 to 4 week rest period. Dose: 2,330 mcg (2.33 mg) total blend daily, providing approximately 1.7 mg GHK-Cu, 0.33 mg TB-500, and 0.33 mg BPC-157 per injection.
Reconstitution: 3.0 mL per 70 mg vial (~23.3 mg/mL).
Storage: Lyophilized vials frozen; reconstituted solutions refrigerated; use within 4 weeks.
Glutathione (g-L-glutamyl-L-cysteinyl-glycine) is the master antioxidant tripeptide studied for cellular detoxification, oxidative stress reduction, and redox balance. As the most abundant intracellular thiol, glutathione plays a central role in neutralizing free radicals, supporting liver function, enhancing immune cell activity, and protecting against environmental toxins.
GOAL: Support antioxidant defense, cellular detoxification, and immune function.
SCHEDULE: Daily or every-other-day subcutaneous injections for 4 to 8 weeks.
DOSE RANGE: 100 to 200 mg daily with gradual titration.
RECONSTITUTION: 3.0 mL per 1,500 mg vial (500 mg/mL).
STORAGE: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze-thaw.
The KLOW protocol is a specialized quad-peptide blend combining KPV, GHK-Cu, BPC-157, and TB-500 designed to support tissue repair, reduce inflammation, and promote anti-aging.
Component Breakdown
KPV: Calms inflammation and supports gut health.
GHK-Cu: Rebuilds collagen and improves skin texture.
BPC-157: Repairs and protects musculoskeletal and soft tissues.
TB-500: Accelerates cell migration and coordinated healing.
Administration and Cycling
Typical Dosing: Often administered 5 days on and 2 days off.
Cycle Length: Commonly run for 6 to 8 weeks, followed by a 2-to-4-week break.
Reconstitution: Vials (frequently 35 mg total or similar blends) are mixed with 3–5 mL of bacteriostatic water as guided by a clinical provider or research parameters.
MOTS-c is a 16 amino acid mitochondrial-derived peptide (MDP) that acts as a metabolic regulator, primarily through AMPK activation. Preclinical studies show it enhances insulin sensitivity, promotes fat oxidation, improves exercise capacity, and counters age-related metabolic decline.
GOAL: Support metabolic homeostasis, insulin sensitivity, and age-related physical performance based on preclinical evidence.
Schedule: Daily subcutaneous injections for 8 to 12 weeks (extend to 16 weeks if desired).
Dose Range: 200 to 1,000 mcg daily with gradual titration over 10 weeks.
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL).
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze-thaw.
GOAL: Support cellular energy metabolism, DNA repair pathways, and mitochondrial function through exogenous NAD+ supplementation.
SCHEDULE: Daily subcutaneous injections for 8 to 16 weeks with gradual dose titration.
DOSE: Range50 to 100 mg daily; start low (50 mg) and increase by ~25 mg weekly as tolerated.
RECONSTITUTION: 3.0 mL per 500 mg vial (166.7 mg/mL).
STORAGE: Lyophilized frozen; reconstituted refrigerated for up to 14 days; protect from light.
GOAL: Support significant weight reduction and metabolic improvements through triple-receptor activation.
SCHEDULE: Weekly subcutaneous injections for 12 to 48 weeks (clinical trials ranged 36 to 48 weeks).
DOSE: Range2 to 12 mg weekly with gradual 4-week titration steps.
RECONSTITUTION:1.0 mL per 10 mg vial (~10.0 mg/mL).
STORAGE: Lyophilized frozen at -20 °C; reconstituted refrigerated for up to 4 weeks.
Once-daily subcutaneous protocol for mitochondria-targeted elamipretide research.
SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing electron transport chain complexes and reducing reactive oxygen species production while enhancing ATP synthesis. This peptide has demonstrated protective effects in preclinical models of heart failure, neurodegenerative disease, and age-related muscle atrophy, and received FDA accelerated approval in 2025 as the first treatment for Barth syndrome.
The Wolverine protocol (or stack) is an experimental peptide therapy combining BPC-157 and TB-500 designed to accelerate soft tissue repair, reduce inflammation, and mimic rapid healing.
Component Breakdown
BPC-157: Targets localized healing in tendons, ligaments, muscle, and the gut via blood vessel formation (angiogenesis).
TB-500: Provides systemic support by improving cell migration, tissue elasticity, and actin regulation. [1, 2, 3]
Typical Administration and Dosing (Experimental/Unregulated)
No results match your search. Try removing a few filters.
